74 reports

Immunotoxicity of monoclonal antibodies. mAbs; ##(##): ##-## Duan C, et al. (2015).

  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Johnson & Johnson
  • Pfizer Inc.

METABOLIC MONOCLONAL ANTIBODIES THIRD ONE?

  • Monoclonal Antibody
  • Protein Therapy
  • Vaccine
  • Market Size
  • Pfizer Inc.

METABOLIC MONOCLONAL ANTIBODIES THIRD ONE?

  • Monoclonal Antibody
  • Protein Therapy
  • Vaccine
  • Forecast
  • Pfizer Inc.
  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, ANNUAL REVENUE FORECAST FOR KEY PRODUCTS ($M), 2017-2024

For example, anti-fibrillin-## antibodies can activate fibroblasts, and antibodies to matrix metalloproteinase-## (MMP-##) and MMP-## can prevent the breakdown of excessive collagen.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Monoclonal Antibody
  • Pfizer Inc.
  • tremelimumab

Distinct PD-L## binding characteristics of therapeutic monoclonal antibody durvalumab.

  • Breast Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

THESE TWO THERAPIES ARE MONOCLONAL ANTIBODY (MAB) PRODUCTS THAT TARGET INTERLEUKIN RECEPTORS, AND TYPIFY THE GROWING PROMINENCE OF MABS IN THE TREATMENT OF RESPIRATORY DISEASES.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.

This should lead to the development of novel diagnostic tools and products such as monoclonal antibodies.

  • Monoclonal Antibody
  • Neurological Disorder
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.

Monoclonal antibodies (mAbs) are the newest class of drugs, predominately used in the treatment of psoriasis.

  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.

TWO MONOCLONAL ANTIBODY (MAB) THERAPIES ARE UNDERGOING CLINICAL TRIALS, ONE OF WHICH IS IN PHASE III.

  • Biosimilar
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.

UNLIKE THE GENERICS OF SMALL MOLECULES, WHICH ARE OFTEN PRICED AT A SUBSTANTIAL DISCOUNT TO THE ORIGINATOR BRAND, BIOSIMILARS OF THE MONOCLONAL ANTIBODY (MAB) THERAPIES FOR PLAQUE PSORIASIS ARE PRICED ONLY MARGINALLY LOWER THAN THE CORRESPONDING BIOLOGIC BRAND.

  • Dermatological Condition
  • Monoclonal Antibody
  • Therapy
  • World
  • Pfizer Inc.

ELI LILLY' S MIRIKIZIMAB IS A HUMANIZED MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS TO THE P## SUBUNIT UNIQUE TO CYTOKINE IL-##, NEUTRALIZING ITS ACTIVITY.

  • Hospital
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.
  • Papillary Pipeline Drug Molecules
  • a. Advent of Checkpoint Inhibitors

Twelve are monoclonal antibody including two antibody-drug conjugates.

  • Cancer
  • Monoclonal Antibody
  • Renal Cancer
  • Therapy
  • Pfizer Inc.

Monoclonal antibodies had one deal with an undisclosed deal value.

  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Clearside Biomedical, Inc.
  • Pfizer Inc.
  • Disorder
  • 9.1.3 INVESTIGATIONAL NEW DRUG/CLINICAL TRIAL AUTHORIZATION-FILED

Monoclonal antibodies dominated the RA licensing deals market, accounting for ## of the ## deals (##. ##%).

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Pfizer Inc.
  • PFIZER - PF-06439535
  • PFIZER - TRASTUZUMAB

FIGURE ##-##: MONOCLONAL ANTIBODIES IN CANCER TREATMENT, OPDIVO PERFORMANCE VS.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.
  • CLINICAL TRIALS - LEADING INDUSTRY SPONSORS
  • TOP INDUSTRY SPONSORS OF CLINICAL TRIALS IN AXSPA

WITH MOST OF THE PHASE I DRUGS BEING MONOCLONAL ANTIBODIES, THIS STILL REMAINS THE MOLECULE TYPE OF CHOICE FOR FUTURE DRUG DEVELOPMENT. ## Source: GlobalData, Pharma Intelligence Center [Accessed May 2018] ## ## ## ## ## ## ## ## ## ## ## ## Fusion Protein

  • Clinical Trial
  • Monoclonal Antibody
  • United States
  • Market Competition
  • Pfizer Inc.

TREGALIZUMAB IS ANOTHER HIGH-RISK PHASE II INVESTIGATIONAL DRUG, AN ANTI-CD## MONOCLONAL ANTIBODY, INDUCING SELECTIVE ACTIVATION OF REGULATORY T-CELLS.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Pfizer Inc.

Herceptin is a monoclonal antibody targeting the HER## receptor.

  • Breast Cancer
  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.
  • Executive Summary

This segment consists largely of premium systemic monoclonal antibodies (mAb), which are highly commercially successful due to their widespread use and high cost.

  • Autoimmune Disease
  • Immunology
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.
  • KEY COMPANIES IN THE ULCERATIVE COLITIS MARKET IN THE 7MM, 2015
  • 9.1 OVERVIEW

IT IS GUT-SELECTIVE MONOCLONAL ANTIBODY AND HAS SUPERIOR SAFETY PROFILE COMPARED TO ANTI-TNFS.

  • Autoimmune Disease
  • Epidemiology
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.

Figure ##: Cancer Supportive Care Market, Global, Annual Revenue for Neulasta ($bn), 2011- ##. ## Xgeva (denosumab) - Amgen Xgeva (denosumab) is a human monoclonal antibody (mAb) approved in 2010 to help prevent skeletal-related events (SRE) in patients with cancer that had metastasize

  • Blood Disease
  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.
  • Breast Cancer Therapeutics Market, Global, Co-development Deals in Southeast Asia and Deals with Disclosed Values, 2006-

Herceptin is the gold standard monoclonal antibody (mAb) for the treatment of HER##positive disease, and is prescribed in nearly all settings.

  • Breast Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

The drug candidate is a subcutaneously administered monoclonal antibody.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Mycenax
  • Pfizer Inc.

Avastin is a recombinant, humanized, monoclonal immunoglobulin (IgG) ## antibody developed by Roche.

  • Lung Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

In particular, the diversification in pharmaceutical therapeutics has led to a transformation in both the clinical and commercial landscape with the advent of monoclonal antibodies (mAb).

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Pfizer Inc.

MediGene AG BioInvent International AB Genmab A/ S Ablynx NV Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical mAb mAb mAb mAb mAb mAb mAb Hormonal signaling Undisclosed Undisclosed Undisclosed Undisclosed Undisclosed Undisclosed Monoclonal

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • Pfizer Inc.

PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF A HUMAN ANTI-IL-## monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Monoclonal Antibody
  • Pfizer Inc.
  • NULL

Human anti-PD-L## monoclonal antibody, Immune checkpoint inhibitor, Oncolytic.

  • Cancer
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • Pfizer Inc.

Xilonix (MABp##) is a first-in-class human immunoglobulin G## (IgG##) monoclonal antibody being developed by XBiotech to treat the debilitating symptoms of colorectal cancer, including cachexia.

  • Cancer
  • Chemotherapy
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.
  • 4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE
  • IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

MONOCLONAL ANTIBODIES ARE MAINLY OF THREE TYPES SUCH AS NAKED MONOCLONAL ANTIBODIES, BISPECIFIC MONOCLONAL ANTIBODIES AND CONJUGATED MONOCLONAL ANTIBODIES.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Pfizer Inc.